Khurram Jamil is Chief Medical Officer at GALECTIN THERAPEUTICS INC (GALT). They have made 1 open-market trade across 1 company since 2024, most recently 2026-07-14.
CIK 0002032345
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GALT | 16,250 | $59K |
Shares reported on the most recent Form 4, priced at the 2026-07-16 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GALT | SELL · 10b5-1 | 2026-07-14 | 2026-07-16 | $5.13 | $83K | -19.2% | -16.9% | -13.1% |
| GALT | SELL · 10b5-1 | 2026-06-26 | 2026-06-30 | $5.04 | $262K | -0.4% | -29.8% | -14.6% |
| GALT | SELL · 10b5-1 | 2026-06-23 | 2026-06-25 | $3.14 | $24K | +7.0% | -19.6% | -3.9% |
| GALT | SELL · 10b5-1 | 2026-05-26 | 2026-05-28 | $3.10 | $2K | -4.5% | +95.5% | +64.0% |
| GALT | SELL | 2026-01-02 | 2026-01-06 | $3.87 | $232K | -12.4% | -18.4% | -26.2% |
| GALT | SELL · 10b5-1 | 2025-12-31 | 2026-01-05 | $4.07 | $33K | -18.4% | -23.3% | -33.7% |
| GALT | SELL · 10b5-1 | 2025-12-17 | 2025-12-19 | $7.04 | $137K | -6.0% | -30.6% | -35.0% |
| GALT | SELL · 10b5-1 | 2025-11-13 | 2025-11-14 | $5.47 | $644K | +2.7% | +16.0% | -49.9% |
| GALT | SELL · 10b5-1 | 2024-12-23 | 2024-12-26 | $0.88 | $12K | +25.4% | +35.4% | +82.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.